Sequana Medical NV
XBRU:SEQUA
Sequana Medical NV
PP&E Net
Sequana Medical NV
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sequana Medical NV
XBRU:SEQUA
|
PP&E Net
€3.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Nyxoah SA
XBRU:NYXH
|
PP&E Net
€8.2m
|
CAGR 3-Years
16%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
Ion Beam Applications SA
XBRU:IBAB
|
PP&E Net
€55.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Sequana Medical NV
Glance View
Sequana Medical NV is a commercial stage medical device company, which engages in the design, development, manufacture, and commercialization of medical device. The company is headquartered in Ghent, Oost-Vlaanderen and currently employs 60 full-time employees. The company went IPO on 2019-02-11. The firm focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
See Also
What is Sequana Medical NV's PP&E Net?
PP&E Net
3.6m
EUR
Based on the financial report for Jun 30, 2025, Sequana Medical NV's PP&E Net amounts to 3.6m EUR.
What is Sequana Medical NV's PP&E Net growth rate?
PP&E Net CAGR 5Y
39%
Over the last year, the PP&E Net growth was 2%. The average annual PP&E Net growth rates for Sequana Medical NV have been 11% over the past three years , 39% over the past five years .
